NCT06558227View on ClinicalTrials.gov

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

October 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

ZG005 for Injection

10 mg/kg or 20 mg/kg administered intravenously Q3w

BIOLOGICAL

Bevacizumab

15 mg/kg administered intravenously Q3w

BIOLOGICAL

Sintilimab

200 mg administered intravenously Q3w

BIOLOGICAL

Bevacizumab

15 mg/kg administered intravenously Q3w

Trial Locations (1)

Unknown

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY